Pharma

Your Article Summary

See Latest Articles

Landmark trial shows Boston Scientific CRT-Ds slow the progression of heart failure in asymptomatic and mildly symptomatic patients
Boston Scientific, 06/24/09

Boston Scientific Corporation and the University of Rochester Medical Center announced that the landmark MADIT-CRT trial has met its primary endpoint. Preliminary results show Boston Scientific cardiac resynchronization therapy defibrillators to be associated with a significant 29 percent reduction in death or heart failure interventions when compared to traditional implantable cardiov

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09

A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09

Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09

 See all of Drug Trials